Booth-To-Go: The Booth That Followed Doctors
Author: Qoolo Team
Most congress content disappears the moment the event ends.
Not because doctors didn't care. Because booth experiences were built for a different kind of attention. Stop. Watch. Wait. Remember later. But that's not how HCPs move through congresses anymore.
They move fast. Between sessions. Between conversations. On their phones. Halfway to the next meeting. And yet life sciences still spends over $800 million every year building static booth experiences that only work in the moment they're standing there.
This case study follows one top-20 pharma brand that decided to challenge that model. Instead of treating the booth as the destination, they turned it into the starting point transforming congress materials into a mobile-first micro-content experience doctors could access instantly, revisit later, and engage with on their own terms.
No app downloads. No waiting for follow-up emails. No dependency on someone standing next to a screen. Just scientific content built for how HCPs actually consume information during live events.
This isn't just a booth case study. It's what happens when congress content stops being built for the booth and starts being built for the moment.
Curious to read more?
Download the full white paper:
Your booth budget is significant. Your booth window is three days. What happens to that content on day four? The build. The shift. The results. Download now.
Browse similar resources
Reimagining HCP Engagement: The Advantage of Micro-Content in Life Sciences
Your team is producing more content than ever. HCPs are opening less of it than ever. That gap has a name now. And a fix. This white paper gives Medical Affairs and brand leaders the full picture why traditional content formats are collapsing under the reality of modern HCP attention, what micro-content changes across medical and commercial functions, and how leading teams are starting to build for the moments where engagement actually happens. Not a trend piece. It’s what happens when pharma content collides with reality.